Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IBIO-600 · 1 trial · 1 indication
Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.
| Arm | Type | Description |
|---|---|---|
| IBIO-600 (Cohort 1) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 2) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 3) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 4) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| IBIO-600 | DRUG | IBIO-600 Subcutaneous injection |
| Placebo | DRUG | Matching placebo; subcutaneous injection |
Inclusion Criteria: * Aged 18 to 65 years of age * In good general health, with no significant medical history * BMI between ≥ 27.0 and ≤ 34.90 kg/m2 * History of self-reported stable body weight (defined as change of no more or less than ± 5%) within 90 days of Screening. * Willingness to refrain ...
IBIO-600 is an investigational small molecule being developed for the treatment of overweight and obesity. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in adults who are overweight or obese.
IBIO-600 targets myostatin, a protein that regulates muscle growth. By targeting myostatin, the drug may influence muscle mass and metabolism, which could be relevant for weight management. This mechanism is being evaluated in early-stage clinical trials for overweight and obesity.
IBIO-600 is being developed by iBio, Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol IBIO. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and other characteristics in overweight or obese adults.
IBIO-600 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is recruiting participants to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose.
IBIO-600 is being studied in a Phase 1 clinical trial registered as NCT07487376. This randomized, double-blind, placebo-controlled study evaluates a single dose of IBIO-600 in overweight or obese adults. The trial is recruiting 32 participants in Australia and is not yet completed.
IBIO-600 is a distinct investigational small molecule developed by iBio, Inc. No alternative names for this drug have been disclosed. It is being studied specifically for overweight and obesity, and its mechanism of action involves targeting myostatin, a protein involved in muscle regulation.